Predicting Outcomes in Patients With Diffuse Large B-Cell Lymphoma Treated With Standard of Care

In diffuse large B-cell lymphoma (DLBCL), predictive modeling may contribute to targeted drug development by enrichment of the study populations enrolled in clinical trials of DLBCL investigational drugs to include patients with lower likelihood of responding to standard of care. In clinical practic...

Descripción completa

Detalles Bibliográficos
Autores principales: Galaznik, Aaron, Reich, Christian, Klebanov, Greg, Khoma, Yuriy, Allakhverdiiev, Eldar, Hather, Greg, Shou, Yaping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421613/
https://www.ncbi.nlm.nih.gov/pubmed/30906191
http://dx.doi.org/10.1177/1176935119835538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421613/
https://www.ncbi.nlm.nih.gov/pubmed/30906191
http://dx.doi.org/10.1177/1176935119835538

Ejemplares similares